Premium
Antibody inhibition of cytomegalovirus: the role of natural killer and macrophage effector cells
Author(s) -
Forthal D.N.,
Phan T.,
Landucci G.
Publication year - 2001
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1034/j.1399-3062.2001.00006.x
Subject(s) - effector , immunology , antibody , peripheral blood mononuclear cell , antibody dependent cell mediated cytotoxicity , medicine , cytomegalovirus , foreskin , macrophage , virology , in vitro , biology , cell culture , virus , herpesviridae , monoclonal antibody , viral disease , biochemistry , genetics
To explore mechanisms by which antibody might inhibit cytomegalovirus (CMV), we measured the ability of intravenous CMV‐IgG (CytoGam® to reduce viral yield in the presence of effector cells. Foreskin fibroblasts were infected with a clinical strain of CMV, and CytoGam® was added along with effector cells consisting of either unfractionated peripheral blood mononuclear cells (PBMCs), natural killer (NK) cells, or macrophages. The combination of CytoGam® and either of the effector cell types markedly inhibited established CMV infection in vitro . In addition, CytoGam® combined with effector cells protected the monolayer from CMV‐induced cytopathic effects. Antibody‐dependent, effector cell‐mediated functions may underlie the ability of CytoGam® to prevent or modulate CMV infection in vivo .